Therapeutic antibodies are among the most successful class of biological therapeutics available to clinicians. These monoclonal antibodies are routinely used for the treatment of autoimmune diseases and in cancer therapies.
They are widely used as a therapeutic agent for treating cancer and various autoimmune disorders. Specific detection, and precise quantification of these components, as well as characterization of subject immune response to them, is necessary to better understand their role and to precisely identify potential contraindications.
|Adalimumab||Humira||TNF inhibitor||autoimmune disease|
|Aflibercept||Eylea, Zaltrap||VEGF-A inhibitor||cancer treatment|
|Bevacizumab||Avastin||VEGF-A inhibitor||cancer treatment|
|Cetuximab||Erbitux||EGFR inhibitor||cancer treatment|
|Etanercept||Enbrel||TNF inhibitor||autoimmune disease|
|Golimumab||Simponi||TNF inhibitor||autoimmune disease|
|Infliximab||Remicade, Remsima||TNF inhibitor||autoimmune disease|
|Omalizumab||Xolair||IgE blocker||allergic asthma|
|Rituximab||Rituxan, Mabthera||B-cell marker CD20 binding||white blood cell cancer|
|Trastuzumab||Herceptin, Herclon||HER2/neu blocker||breast cancer|